Xolair gets black box labeling

The FDA has announced new "black box" labeling for Genentech's Xolair (omalizumab) to address the risk of anaphylaxis in patients using the asthma drug.

The new labeling, the FDA’s strictest, indicates that patient reports following the drug's approval in 2003 through 2006 noted cases of anaphylaxis were seen in roughly two out of 1000 patients.

Genentech collaborates with Novartis on the marketing of Xolair, which had $425 million in global sales last year.


 

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.